Century Therapeutics (IPSC) Piper Sandler 36th Annual Healthcare Conference summary

Platform advantages and technology

• iPSC platform enables unlimited precision genetic editing, supporting advanced synthetic biology applications.

• Single-cell cloning ensures safety and reproducibility, with master cell banks providing consistent products.

• Profitable scalability allows large batch sizes and significant cost reductions compared to autologous and donor-derived therapies.

• Ability to generate multiple immune effector cells, including NK, gamma delta T, and alpha beta T cells.

• Allo-evasion edits enable cells to coexist with patient immune systems, supporting repeat dosing.

Clinical progress and data updates

• CNTY-101, an iPSC-derived NK cell therapy with six genetic edits, is in phase 1 for B-cell malignancies.

• Recent data show favorable safety, with no DLTs or GVHD, and encouraging efficacy, especially at higher doses.

• Dose level 3B showed an 83% overall response rate and 33% CR rate in heavily pretreated patients.

• Allo-evasion edits improve pharmacokinetics, allowing cell persistence even after immune system recovery.

• Next clinical update for ELIPS-1 is expected in mid-2025.

Pipeline expansion and strategic direction

• CALYPSO-1 phase 1 trial for CNTY-101 in autoimmune diseases now includes four indications, with U.S. and European sites.

• Enrollment cadence will determine timing for initial data release across these indications.

• Acquisition of Clade Therapeutics expanded the preclinical pipeline, focusing on alpha beta T, gamma delta T, and NK cells.

• Preclinical prioritization ongoing, with first data from alpha beta T cell programs to be presented at ASH.